Biodistribution, pharmacokinetics and metabolism of interleukin‐1 receptor antagonist (IL‐1RA) using [18F]‐IL1RA and PET imaging in rats
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE: Positron emission tomography (PET) has the potential to improve our understanding of the preclinical pharmacokinetics and metabolism of therapeutic agents, and is easily translated to clinical studies in humans. However, studies involving proteins radiolabelled with clinically relevant PET isotopes are currently limited. Here we illustrate the potential of PET imaging in a preclinical study of the biodistribution and metabolism of 18 F‐labelled IL‐1 receptor antagonist ([18 F]IL‐1RA) using a novel [18 F]‐radiolabelling technique. EXPERIMENTAL APPROACH: IL‐1RA was radiolabelled by reductive amination on lysine moieties with [18 F]fluoroacetaldehyde. Sprague‐Dawley rats were injected intravenously with [18 F]IL‐1RA and imaged with a PET camera for 2 h. For the study of IL‐1RA metabolites by ex vivo γ‐counting of samples, rats were killed 20 min, 1 h or 2 h after injection of [18 F]IL‐1RA. KEY RESULTS: [18 F]IL‐1RA distribution into the major organs of interest was as follows: kidneys >> liver > lungs >> brain. In lungs and liver, [18 F]IL‐1RA uptake peaked within 1 min post‐injection then decreased rapidly to reach a plateau from 10 min post‐injection. In the brain, the uptake exhibited slower pharmacokinetics with a smaller post‐injection peak and a plateau from 6 min onward. IL‐1RA was rapidly metabolized and these metabolites represented ∼40% of total activity in plasma and ∼80% in urine, 20 min after injection. CONCLUSIONS AND IMPLICATIONS Preclinical PET imaging is a feasible method of assessing the biodistribution of new biological compounds of therapeutic interest rapidly. The biodistribution of [18 F]IL‐1RA reported here is in agreement with an earlier study suggesting low uptake in the normal brain, with rapid metabolism and excretion via the kidneys.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
The role of inflammation in CNS injury and disease
Lucas, S., Rothwell, N. J., & Gibson, R. M. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706400 · Cited by 1,272 · cited 1×
“Both experimental models and clinical studies suggest that IL-1 receptor agonists and their pro-inflammatory actions are detrimental in such neuropathological conditions, whereas IL-1 antagonism seems beneficial (see Allan, et al., 2005 and Lucas et al., 2006).”
BackgroundSelf-citationInterleukin-1 and neuronal injury
Allan, S. M., Tyrrell, P. J., & Rothwell, N. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1664 · Cited by 992
Self-citationMogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90508-8 · Cited by 855 · cited 2×
“, 2007), Parkinson’s disease (Mogi et al., 1994; Ferrari et al., 2006; Godoy et al., 2008) and epilepsy (Bartfai et al.”
BackgroundThe role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective
Shaftel, S. S., Griffin, W. S. T., & O'Banion, M. K. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-7 · Cited by 565
Shaftel, S. S., Kyrkanides, S., Olschowka, J. A., Miller, J.-N. H., Johnson, R. E., & O’Banion, M. K. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31450 · Cited by 433 · cited 3×
“However, some controversy still exists in chronic neurodegenerative conditions such as Alzheimer’s (Shaftel et al., 2007; 2008) and Parkinson’s diseases (Tansey et al., 2007).”
BackgroundPott Godoy, M. C., Tarelli, R., Ferrari, C. C., Sarchi, M. I., & Pitossi, F. J. (2008) · Brain · doi:10.1093/brain/awn101 · Cited by 335 · cited 2×
“, 2007), Parkinson’s disease (Mogi et al., 1994; Ferrari et al., 2006; Godoy et al., 2008) and epilepsy (Bartfai et al.”
BackgroundFerrari, C. C., Pott Godoy, M. C., Tarelli, R., Chertoff, M., Depino, A. M., & Pitossi, F. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.013 · Cited by 235
Cited by
IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice
Petrasek, J., Bala, S., Csak, T., Lippai, D., Kodys, K., Menashy, V., Barrieau, M., Min, S.-Y., Kurt-Jones, E. A., & Szabo, G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60777 · Cited by 735
“administration (Figure 6C), most likely due to the pronounced renal accumulation (Figure 6D) and rapid elimination of IL-1Ra in rodents (18).”
BackgroundBioanalytical Chemistry of Cytokines–a Review
Stenken, J. A., & Poschenrieder, A. J. (2015) · Analytica Chimica Acta · doi:10.1016/j.aca.2014.10.009 · Cited by 302
Dogra, P., Adolphi, N. L., Wang, Z., Lin, Y.-S., Butler, K. S., Durfee, P. N., Croissant, J. G., Noureddine, A., Coker, E. N., Bearer, E. L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06730-z · Cited by 257
Schmidt, E.-M., Linz, B., Diekelmann, S., Besedovsky, L., Lange, T., & Born, J. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.11.012 · Cited by 41
“Although with peripheral administration levels of IL-1ra achieved per gram brain tissue are only 0.01–0.6% of the injected dose, such levels are within the range of drugs known to produce strong neuromodulatory actions (e.g., Cawthorne et al., 2011; Clark et al., 2008; Gutierrez et al., 1994).”
BackgroundInfluential
Metadata
- Authors
- Cawthorne, C., Prenant, C., Smigova, A., Julyan, P., Maroy, R., Herholz, K., Rothwell, N., & Boutin, H.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-01-12
- Volume
- 162
- Issue
- 3
- Pages
- 659-672
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1569828475
- Cited by
- 54
- References
- 8
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biodistribution, pharmacokinetics and metabolism of interleukin‐1 receptor antagonist (IL‐1RA) using [18F]‐IL1RA and PET imaging in rats. https://app.cochat.ai/papers/10.1111/j.1476-5381.2010.01068.x
- The paper
- Cawthorne, C., Prenant, C., Smigova, A., Julyan, P., Maroy, R., Herholz, K., Rothwell, N., & Boutin, H. (2011). Biodistribution, pharmacokinetics and metabolism of interleukin‐1 receptor antagonist (IL‐1RA) using [18F]‐IL1RA and PET imaging in rats. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2010.01068.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.